StemCell Therapy

Lille (France), Cambridge, MA; September 28, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe and chronic liver diseases, today announced its first half-year 2022 financial results and provided a corporate update.

View original post here:
GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update

NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Mark Frattini, M.D., Ph.D., as Chief Medical Officer, effective immediately.

Original post:
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, has filed a response to the complaint of, and counterclaims against, Janssen Biopharma in California State Superior Court for the County of San Mateo.

Read the original:
Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud

Saint Herblain (France), September 28, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the “Company”), a specialty vaccine company, today announced its intention to issue and sell, subject to market conditions, approximately $40 million of its ordinary shares in a global offering to specified categories of investors comprised of (i) a public offering of its American Depositary Shares (“ADSs”), each representing two ordinary shares, in the United States (the “U.S. Offering”) and (ii) a concurrent private placement of its ordinary shares in certain jurisdictions outside of the United States (the “European Private Placement” and together with the U.S. Offering, the “Global Offering”).

Go here to read the rest:
Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares

Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

Read the original here:
Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) announces the release of a corporate update which highlights the company’s recent team meeting in France, the current pipeline, and the latest deal structure.

Read the original post:
Sirona Biochem Issues Corporate Update

Through its wholly owned subsidiary BSPG Laboratories, Brains Bio’s new facility is set to become a global research center for cannabinoid research, testing, and commercialization of natural EU GMP API’s Through its wholly owned subsidiary BSPG Laboratories, Brains Bio’s new facility is set to become a global research center for cannabinoid research, testing, and commercialization of natural EU GMP API’s

Follow this link:
Brains Bioceutical Opens UK’s Largest EU GMP-Grade Licensed Cannabinoid Research and Commercial Production Facility

Ad hoc announcement pursuant to Art. 53 LR

Read more:
Santhera Announces Preliminary 2022 Half-year Financial Results Ahead of Full Report Publication by End of October

Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators

TOKYOandSAN FRANCISCO, Sept. 19, 2022 /PRNewswire/ -- Astellas Venture Management LLC (President:William Watt, Ph.D., "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503,President and CEO:Kenji Yasukawa, Ph.D., "Astellas"), and Mission Bay Capital BioLabs ("MBC BioLabs"), a life-science incubator, today announced their collaboration on the "Astellas Future Innovator Prize" formerly known as the Astellas Golden Ticket competition. Building on over three successful years, the competition offers entrepreneurial scientists or emerging biotechnology start-ups one year's priority usage of MBC BioLabs' state-of-the-art lab facility and access to Astellas' research and development (R&D) capabilities and business leaders.

With a shared commitment to discovering and advancing innovative science for the potential future benefit of patients worldwide, AVM and MBC BioLabs are continuing their partnership to support scientists and early-stage companies to accelerate their novel therapeutic programs, modalities or platforms. The 2022 competition will prioritize innovative research that compliment Astellas' Focus Area Approach and pipeline.

"We are truly thrilled to host the Astellas Future Innovator Prize again this year," said William Watt, President, AVM. "Through our long-term collaboration with MBC BioLabs, we aim to create an environment that encourages innovation to thrive. The Astellas Future Innovator Prize enables us to provide biotech companies with expertise and capabilities to turn an innovative idea into a real solution, which could transform the lives of patients in need around the world."

"We are pleased to continue our partnership with Astellas to uncover the innovators of tomorrow," saidDouglas Crawford, MBC BioLabs General Manager. "The past winners of the Astellas Future Innovator Prize show what can be achieved by combining Astellas' support, advice and expertise with our laboratory incubator, and we are excited to see the result of our ongoing collaboration."

Entrepreneurial scientists, emerging life-science and biotechnology start-ups have untilNovember 4, 2022to enter the Astellas Future Innovator Prize.

About the Astellas Future Innovator Prize at MBC BioLabs

Astellas is offering up to two prizes for pioneering scientists with innovative research that complements Astellas' areas of interest in alignment with its Focus Area Approach and pipeline, including Blindness & Regeneration, Mitochondria, Genetic Regulation, Immuno-Oncology, Cell Therapy, and other areas.

Companies awarded an Astellas Future Innovator Prize will gain one year's priority admission or renewal to MBC BioLabs' state-of-the-art laboratory and access to Astellas' R&D scientists and business leaders. The competition is open fromSeptember 19 to November 4, 2022. Entrepreneurial scientists, emerging life-science or biotechnology start-ups should submit their non-confidential company presentation, including a one-page executive summary, tohttps://www.astellas.com/en/astellasfutureinnovator/san-francisco2022to be considered. The decision to award any Astellas Future Innovator Prize and the assessments underlying such decision, are solely within the judgment of Astellas and are not subject to any objection or appeal.

The 2021 Astellas Future Innovator Prize winners were Vcreate and Weatherwax Biotechnologies, chosen for the potential of their innovations to deliver therapeutic advances for unmet medical needs and their potential synergy with Astellas' Focus Area Approach.

For further information, please go to:https://www.astellas.com/en/astellasfutureinnovator/, where you can also find submission guidance for your non-confidential company presentation and executive summary.

About Astellas Venture Management LLC

AVM is the wholly-owned venture capital organization within Astellas, dedicated to supporting pre-clinical, cutting-edge science that can bring VALUE to patients. For over 15 years, AVM has provided equity investments to private, early-stage companies developing therapeutic programs and platform technologies, helping them to advance their innovations faster. AVM is a strategic investor, making investments in science that will enhance the current Astellas R&D pipeline or that could catalyze new directions in discovery research. For more information, please visit our website athttps://www.astellas.com/en/astellasfutureinnovator/.

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website athttps://www.astellas.com/en.

About MBC BioLabs

MBC BioLabs is dedicated to helping life-science startups succeed. By renting space as small as a single bench and providing these entrepreneurial scientists with access to millions of dollars of equipment, MBC BioLabs allows companies to be fast, focused, and frugal. It has three sites: one in the Dogpatch neighborhood inSan Franciscoand two campuses inSan Carlos, California. Each site has a complete molecular biology core facility that allows companies to do experiments on day one. MBC BioLabs has partnerships with leading pharmaceutical and life-science companies as well as a built-in venture capital firm, Mission BioCapital. These partnerships provide entrepreneurs with valuable insights about where to focus their efforts and accelerates the innovation pipeline. Since opening in 2013, MBC BioLabs has helped launch and grow 290 companies. These companies have brought 58 programs to the clinic, produced 13 approved diagnostics, and raised over $14 billion.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas'intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

View original content to download multimedia:https://www.prnewswire.com/news-releases/astellas-and-mbc-biolabs-announce-astellas-future-innovator-prize-to-help-biotech-start-ups-accelerate-early-drug-discovery-and-research-efforts-301627710.html

SOURCE Astellas Pharma Inc.

Read more:
Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts -...

A child getting her eyes checked.

Eye disease such as cataracts is a leading cause of blindness globally and affects a lot of our elderly in Fiji as well.

However, children are not being spared as cataract cases in our young are normally congenital or pediatric.

Pacific Eye Institute Ophthalmologist, Dr Elenoa Raikabakaba says cataracts naturally happen in older patients and is not as common in children.

Some cataracts are associated with other syndromes. The cases we have here, some are associated with other systemic diseases and for some, its of course trauma.

Dr Raikabakaba says early treatment in children is imperative before they reach what is called a critical age.

There is something called critical age so if your child is past the critical age, and if you are waiting for those to be adults and then you treat it; it may not improve their vision. If you think your child needs help, get them to be seen.

Specialists at the Pacific Eye Institute are calling on Fijians to get their eyes checked if they have difficulties with their eyesight and seek proper medical treatment.

Here is the original post:
Treating cataracts before 'critical age' imperative FBC News - FBC News

PARIS--(BUSINESS WIRE)--Regulatory News:

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate in the following industry and investor conferences:

The Business of Rare Policy SummitSeptember 20, 2022 - Washington DC, USBernard Gilly, Co-Founder & Chief Executive Officer, will take part in a panel discussion entitled "Business of Rare: State of the Industry" at 11:15 am EDT / 5:15 pm CEST.

GenSight Biologics is a headline sponsor of the conference and will also host a reception entitled "A Rare Pairing" at 4:30 pm EDT / 10:30 pm CEST.

Chardan's 6th Annual Genetic Medicines ConferenceOctober 3 - 4, 2022 - New York, USBernard Gilly, Co-Founder & Chief Executive Officer, and Thomas Gidoin, Chief Financial Officer, will attend in person on October 4, 2022, present in a fireside chat at 2.30 pm EDT / 8.30 pm CEST, and host investor meetings.

The fireside chat will be webcast live and in replay using this link.

4th Annual HealthTech Innovation Days (HTID) 2022October 13 - 14, 2022 - Paris, France & VirtualBernard Gilly, Co-Founder & Chief Executive Officer, and Thomas Gidoin, Chief Financial Officer, will attend in person and host investor meetings.

BTIG Ophthalmology Day 2022November 29, 2022 - VirtualBernard Gilly, Co-Founder & Chief Executive Officer, and Thomas Gidoin, Chief Financial Officer, will participate and host investor meetings.

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics lead product candidate, LUMEVOQ (GS010; lenadogene nolparvovec), is an investigational compound and has not been registered in any country at this stage; a marketing authorization application is currently under review by the EMA for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

About LUMEVOQ (GS010; lenadogene nolparvovec)

LUMEVOQ (GS010; lenadogene nolparvovec) targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform, arising from research conducted at the Institut de la Vision in Paris, which, when associated with the gene of interest, allows the platform to specifically address defects inside the mitochondria using an AAV vector (Adeno-Associated Virus). The gene of interest is transferred into the cell to be expressed and produces the functional protein, which will then be shuttled to the mitochondria through specific nucleotidic sequences in order to restore the missing or deficient mitochondrial function. LUMEVOQ was accepted as the invented name for GS010 (lenadogene nolparvovec) by the European Medicines Agency (EMA) in October 2018. LUMEVOQ (GS010; lenadogene nolparvovec), is an investigational compound and has not been registered in any country at this stage; a marketing authorization application is currently under review by the EMA.

Originally posted here:
GenSight Biologics to Present at Upcoming Industry and Investor Conferences - Business Wire

The U.S. Department of Health and Human Services (HHS) today announced actions the department will take following theExecutive Ordersigned September 12, 2022 by President Biden launching a National Biotechnology and Biomanufacturing Initiative (NBBI).

This initiative will help drive research and development, improve access to quality federal data, grow domestic manufacturing capacity, expand market opportunities for biobased products, train a diverse and skilled workforce, streamline regulatory processes for products of biotechnology, advance biosafety and biosecurity to reduce risk, protect the U.S. biotechnology ecosystem, and build a thriving and secure global bioeconomy with partners and allies.

In its implementation of the Executive Order, HHS intends to leverage biotechnology and biomanufacturing in order to achieve medical breakthroughs, reduce the overall burden of disease, and improve health outcomes. HHS will lead the U.S. government in strategically advancing biosafety and biosecurity innovation as part of a growing bioeconomy, to ensure biotechnology research and development and biomanufacturing infrastructure break new ground while reducing risk.

Building on the departments successes at bolstering the resilience of the domestic public health supply chain and on continued collaboration and partnership with the American private sector, HHS welcomes a whole-of-government approach to secure U.S. leadership and stewardship of an equitable, safe, and secure bioeconomy. The COVID-19 pandemic has highlighted the departments ability to foster innovative biotechnological treatments, diagnostics, and vaccines swiftly and safely as well as HHS ability to facilitate a more flexible regulatory environment in such circumstances.

With the launch of NBBI, HHS will:

More:
Fact Sheet - HHS.gov

Thank you very much to Jake and for the whole White House team here for the amazing work youve done to get us to this point.

At the Defense Department, this moment in the bioeconomy matters for a lot of reasons.

First, we know that biotechnology and biomanufacturing have transformative potential for our mission at DoD to defend the nation.

It helps us improve capabilities, solve logistics challenges in ways that are sustainable, to Secretary Granholms point, and to protect our people.

And of course we know that strategic competitors like China are themselves prioritizing these technologies. They want to displace U.S. leadership and they want to challenge our competitiveness.

Under Secretary Austins leadership at DoD, we know, though, that we have what it takes here in the U.S. to really footstomp what Jake said earlier we have here, the ability, the ingenuity, the resolve to lead the way, and we have the right kind of innovation ecosystem to make it happen.

So, what can DoD do to help in this space?

Well, over the next five years, DoD will be investing nearly $1.5 billion dollars to expand U.S. bioindustrial manufacturing infrastructure, strengthen biosecurity and cybersecurity at those facilities, and use biotechnology to bolster our supply chains.

The goal, really, is to help be a key catalyst for a domestic bioindustrial manufacturing base, and more quickly turn basic and applied research into operational prototypes and reliable, reproducible products that can be made at scale.

We believe these investments will incentivize biotech innovation and manufacturing capacity for products important both for commercial and defense supply chains, such as critical chemicals for lubricants, energetics, and fuels.

This investment really builds on a history of groundbreaking DoD investment in the biotech space.

You can think about DARPAs work 10 years ago that kickstarted a rapid-response mRNA vaccine platform for infectious diseases, or more recently funding that the department has provided for some of the early wastewater assessment work for COVID, which has great applications for force protection against the coronavirus or future pandemics and has offered spin-off potential for U.S. and overseas communities grappling with biothreats.

And I also understand I think we have here with us today two of DoDs nine Manufacturing Innovation Institutes, BioMADE and BioFabUSA, so thank you to them for all the great work theyre doing.

Going forward, we expect our focus on biotechnology and biomanufacturing to be transformative for what we do at DoD for our forces.

Let me just give you an example of some of the things that are already happening:

Those examples arent science fiction, I think as the folks in this room know. Like the institutions, companies and agencies represented here today, theyre proof of one of Americas greatest strategic assets and thats our incredibly-vibrant innovation ecosystem. Its the envy of the world, and we want to help keep it that way.

Thanks very much.

More:
Deputy Secretary of Defense Dr. Kathleen Hicks' Remarks at the White House Summit on Biote - Department of Defense

President Joe Biden on Monday invoked the national effort to land a man on the Moon 60 years ago in a speech touting his Cancer Moonshot initiative, which aims to slash cancer death rates across the United States by half.

President Joe Biden on Monday invoked the national effort to land a man on the Moon 60 years ago in a speech touting his Cancer Moonshot initiative, which aims to slash cancer death rates across the United States by half.

The Democrat was in Boston for an address deliberately echoing John F. Kennedy's famous 1962 "Moonshot speech" in which he called for landing an American on the lunar surface -- something achieved in 1969, after his assassination.

This time, Biden is pushing government-backed efforts to coordinate and fund treatment of cancer, search for cures and generally to prevent the disease through better public health.

Cancer remains the number two cause of death after heart disease and Biden said his Cancer Moonshot can halve death rates over the next 25 years.

"I know we can do this together, because I know this: there's nothing, nothing, nothing beyond our capacity or ability if we work together as the United States of America," he said.

Biden said that as in 1962, when the country was in the thick of the Cold War and domestic tensions were high over civil rights, the United States today is at an "inflection point."

And like Kennedy with his Moon program, Biden said he wanted to set "a national purpose that could rally the American people in a common cause."

- Backing from JFK's daughter -

Caroline Kennedy, daughter of the assassinated JFK and now US ambassador to Australia, said her father had defied the doubters in the 1960s, when "scientists weren't sure even that a Moon landing on the surface of the Moon was possible."

Kennedy, however, "understood the power of the idea" and saw the project as a way to unite the country. "No one embodies that spirit more than President Joe Biden," she said. "As president, he has restored the soul of America."

The battle against cancer is personal for Biden: his son Beau died of brain cancer in 2015 when Biden was vice president to Barack Obama.

Biden noted that cancer "does not discriminate..., it doesn't care if you're a Republican or Democrat."

"I give you my word as a Biden: this Cancer Moonshot is one of the reasons why I ran for president."

The linkage to the Moon program also sought to add to Democratic momentum ahead of November's midterm congressional elections where the Democrats face the possibility of a Republican sweep in Congress, severely complicating the last two years of Biden's first term.

- Change the trajectory -

Biden said his plan will push for cures and ways to manage cancer, turning "more cancers from death sentences into chronic diseases that people can live with."

"We know we can change the trajectory," he said.

The president said he was harnessing funding but also government expertise in high-tech research similar to the defense industry, where public-private partnerships drive innovations in weaponry and other military needs.

A new agency named Advanced Research Projects Agency for Health (ARPA-H) and the White House's new "cancer cabinet" will "increase funding to break log jams and to speed breakthroughs," while getting entrepreneurs support from cutting edge scientists with NASA, the Pentagon and the energy department.

The goal is to "use all the assets we have," Biden said, and this "may require unusual partnerships."

- Biotech boost -

Earlier, Biden signed an executive order meant to bolster the trailblazing US biotech sector's efforts to take on growing commercial rivals in China.

The order brings federal support for "areas that will define US biotechnology leadership and our economic competitiveness in the coming decades," a senior Biden administration official told reporters.

The official said that while US biotech research leads the world, the industrial applications are increasingly in the hands of other countries.

"Unless we translate biotechnology innovation into economic and societal benefits for all Americans, other countries, including and especially China, are aggressively investing in this sector," posing a "risk," the official said.

The White House says the US biotech industry is on the cutting edge of medical advances -- recently seen in the rapid development of vaccines, tests and therapeutics to help manage the Covid-19 pandemic -- but that the potential scope goes much further.

The official speaking to reporters cited studies suggesting that "before the end of the decade, engineering biology holds the potential to be used in manufacturing industry that accounts for more than one third of global output. That's equivalent to almost $30 trillion in terms of value."

Growing areas for biotech industry include new plastics and rubbers, jet fuel, and environmentally friendly fertilizers.

Excerpt from:
Biotechnology to the fore as Biden evokes US Moon mission in renewed cancer fight - HT Tech

Scope of the Global Nano Biotechnology Market

Nano Biotechnology Market Report that covers exclusive and analytical data through the span of Ten years between 2022-2032. This report is exclusive and encompasses in-depth analysis and industry insights on Nano Biotechnology Market. What you will get by reading the report is not just charts, bars, and analytical data but also a better understanding of the market which will in turn help you make decisions in the better interest of your organization.

The QMI research report published on the Global Nano Biotechnology Market is an in-depth study of market share, value, and dynamics and is an extensive study of market trends. In addition, geometric surveys are used for predictive analysis, PESTLE analysis, SWOT analysis, and real-time analytics. This is a recent research study, covering the current COVID-19 impact on the global market.

The Nano Biotechnology market report also offers leading players along with a comprehensive strategic scenario pertaining to market volume and market promotion. The report delivers an in-depth market with detailed research on revenue growth and profit study. Also, various graphs are clearly used to offer the data format for an accurate study of facts and figures. The rapidly shifting market scenario and primary & future evaluation of the influence are featured in the research study.

Click here to get a sample of the premium report: https://www.quincemarketinsights.com/request-sample-84960?utm_source=sk/dj

Competitive Landscape: Global Nano Biotechnology Market

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis: Ablynx (Belgium), Nami Therapeutics (US), Celgene Corporation (US), Nanophase Technologies Corporation (US), Sigma-Aldrich (US), SkyePharma Pharmaceuticals (France), Nano Bridging Molecules SA (Switzerland), XanTecBioanalytics GmbH (Germany), Nanobiotix (France) and Dabur Pharma (India)

A brief study of the major market players and manufacturers has been extensively offered in the report to address several queries of clients and readers. The study is targeted to help in the various business decisions and key investment priorities of major stakeholders with a brief analysis of suppliers, distributors, manufacturers, and traders.

Similarly, in this report, clients are rendered important cues on providers landscape and their current competition strength, which highly influence the development of the global Nano Biotechnology market. Further, leading providers, manufacturing landscape, percentage splits, market revenues, breakdowns of the product scenario, and growth details are studied through primary as well as secondary sources.

Understanding Segmentation: Global Nano Biotechnology Market

The Nano Biotechnology market has been segmented as By Application (Pharmaceuticals, Medical Devies, Medical Research, Food and Agriculture) By Therapeutics (Dental Therapies, Cardiac Therapies, Orthopedic Therapies, Others)

The global Nano Biotechnology market report also gives major data on the basis of comprehensive market segmentation. The global Nano Biotechnology Market segment chapter delivers the company total revenue (financials), sales and revenue generated, price, industry share, production sites and services, and product launches.

This report divides the market into various segments on the basis of type, application, technology, as well as geographical regions. Likewise, the report delivers other data such as product consumption, manufacturing details, production capacity, and supply and demand analysis of the market. For the period 2023-2032, this report delivers the Nano Biotechnology sales, revenue, and market share of this market.

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-84960?utm_source=sk/dj

Regional Analysis of the Global Nano Biotechnology market

The market report delivers a major regional spectrum for market scope, and studies, and analyzes each geographical section of the market. The report also offers a detailed research on major insights such as import, consumption, export, supply, and demand. This research study offers regional analysis for regions such as Europe (Germany, France, United Kingdom, Russia, and Italy), North America (United States, Canada, and Mexico), Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia), South America (Brazil, Argentina), and Middle East & Africa (UAE, Egypt, Saudi Arabia, and South Africa).

The report provides insights on the following pointers:

Market Penetration: Detailed information on the product portfolio of the key market players in the Nano Biotechnology market.

Product Innovation/Development: Comprehensive insights into the upcoming technologies, research, and development activities as well as the product launches in the market.

Competitive Assessment: Assessment of the market strategies, business segments and geographical regions of the leading market players.

Market Development: Detailed information about the growing markets. The report also studies the market for various segments across the geographies.

Market Diversification: Comprehensive information about the new product launches, recent development, untapped geographies, and huge investment made by the market.

Quantitative data:

1. Market Revenue and Growth Rate by Type (Historical and Forecast)2. Market Revenue and Growth Rate by Application, such as Food, Beverages, Pharmaceuticals, Industrial & Chemicals, Cosmetics & Personal Care, Agriculture, Others.3. Market Revenue, Growth Rate, Volume, Type, and Application by Each Country (History and Forecast)4. Revenue, Volume, and YOY Growth Rate by Player (Base Year).

This report provides: 1) An overview of the global market for Nano Biotechnology market and related technologies.2) Analysis of global market trends, yearly estimates, and annual growth rate projections for compounds (CAGRs).3) Identification of new market opportunities and targeted consumer marketing strategies for the global Nano Biotechnology market.4) Analysis of R&D and demand for new technologies and new applications5) Extensive company profiles of key players in the industry.

The researchers have studied the market in-depth and have developed important segments such as product type, application, and region. Each and every segment and its sub-segments are analyzed based on their market share, growth prospects, and CAGR. Each market segment offers in-depth, both qualitative and quantitative information on market outlook.

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying-84960?utm_source=sk/dj

Conclusion

The market overview details includes the extensively classified insights procured through several sources. This market report also follows significant market drivers, challenges, and threats that influence the growth of this market. It is a professional and a thorough study that focuses on primary and secondary drivers, market share, major segments, and regional analysis.

Significant market policies have also been studied from the techno-commercial scenario for getting better outcomes. This research study provides quantified data for current market scenario, along with offering an evaluation of the key market players and their growth strategies.

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Pune, Maharashtra

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Continued here:
Nano Biotechnology Market Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2032 - Digital Journal

Most of us are familiar with the propaganda aimed at glyphosate, the active ingredient in Roundup. For years, activists pushed fake news and disinformation about the seriously benign herbicide, mostly because it was associated with genetically modified crops. Francevowed to seriously curtail usewithin its borders. And now local governments around the U.S.,including New York City, are banning it entirely.

Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

Consider Greenpeaces nonsensical opposition to genetically modified crops. The activist organizationhas promoted outright falsehoodsand lies about GMO crops online and in other formats for years. As a result some Southern African governments decided it was better to let their residents starvethan distribute GMO grainssent by other countries. And everyone knows thatGreenpeaces obstruction of Golden Rice [despite] a letter from 159 Nobel Laureatesbegging them to stop with the disinformation couldnt convince them.

Theres plenty of other examples, like GMO labeling, that I could point to. Unfortunately, were increasingly living in a post-truth world where most people only surround themselves with people they want to believe. And, if anything, its only getting worse. So while standing up to these coordinated attacks when they first develop on social media might not be fun and sexy, its more important than ever.

This is an excerpt. Read the original post here

View original post here:
Viewpoint: Here's how post-truth tactics became central to the anti-biotechnology playbook - Genetic Literacy Project

HARRISON, N.Y., Sept. 19, 2022 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immunogenic dysregulation that drive cancer, announced today that preclinical data on ST101, the company's first-in-class peptide antagonist of C/EBP, were published online in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research. The published data describe preclinical evidence to support the advancement of ST101 as a novel therapy for treating advanced solid tumors. The full manuscript titled "Anti-cancer activity of ST101, a novel antagonist of CCAAT/enhancer binding protein ", can be found online here.

The data in the manuscript detail ST101-antagonism of CCAAT/Enhancer Binding Protein (C/EBP), a basic leucine zipper family transcription factor that is upregulated or overactivated in many cancers, resulting in gene transactivation that drives oncogenesis. ST101 binds C/EBP, preventing its dimerization and enhancing ubiquitin-proteasome dependent C/EBP degradation. ST101 exposure significantly decreases expression of C/EBP target genes including genes responsible for survival, transcription factors and cell cycle-related proteins. The result of ST101 exposure is potent, tumor-specific in vitrocytotoxic activity in cancer cell lines including glioblastoma, breast, melanoma, prostate, and lung cancer, while normal human immune and epithelial cells are not impacted. In vivoxenograft models indicate that ST101 exposure results in potent tumor growth inhibition or regression,both as a single agent and in combination studies.

"The publication of ST101 in Molecular Cancer Therapeutics is an exciting achievement, highlighting the tremendous unmet need for novel therapies to treat solid tumor cancers and the role that ST101 can play to fill this need," said Jim Rotolo, Ph.D., Sapience's VP, Translational Pharmacology and Head of Research. "We are thrilled to publish the mechanism of action of ST101 and showcase the therapeutic promise of disrupting C/EBP-driven oncogenic activity. We look forward to reporting and publishing additional data on ST101 and advancing the program through its ongoing Phase 1-2 study."

In its ongoing Phase 1-2 study, ST101 has demonstrated clinical proof-of-concept with a mRANO-confirmed partial response in a patient with recurrent GBM, a durable RECIST 1.1-confirmed partial response in a patient with cutaneous melanoma and long-lasting stable disease in several additional patients.

About ST101 and the Phase 1-2 StudyST101, a first-in-class antagonist of C/EBP, is currently being evaluated in the Phase 2 portion of an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors (NCT04478279). ST101-101 is an open-label, Phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 in patients with advanced solid tumors. The study consists of two phases: Phase 1 dose escalation/regimen exploration and Phase 2 dose expansion. In the ongoing Phase 2 dose expansion, Sapience is actively enrolling patients with GBM, metastatic cutaneous melanoma, castration-resistant prostate cancer and locally advanced or metastatic hormone-receptor positive breast cancer. In the ongoing dose escalation part of the study, ST101 has demonstrated clinical proof-of-concept with a durable RECIST 1.1-confirmed partial response (PR) in a patient with cutaneous melanoma and evidence of long-lasting stable disease in several additional patients. In the ongoing Phase 2 dose expansion part of the study, ST101 has demonstrated clinical proof-of-concept with a mRANO-confirmed partial response in a patient with recurrent GBM and evidence of long-lasting stable disease in several additional patients.

ST101 has been granted Fast Track designation for recurrent GBM and advanced cutaneous melanoma in patients who have disease progression on or after anti-PD-1/anti-PD-L1 therapy,as well as orphan designations from the FDA for advanced melanoma, glioma and AML, and from the European Commission for the treatment of glioma.

About Sapience TherapeuticsSapience Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing peptide therapeutics to address oncogenic and immunogenic dysregulation that drive cancer. Its pipeline of SPEARs (Stabilized Peptides Engineered Against Regulation) disrupt intracellular protein-protein interactions, enabling targeting of transcription factors which have traditionally been considered undruggable. Sapience's lead program, ST101, is a first-in-class antagonist of C/EBP that has demonstrated clinical proof-of-concept in multiple indications. For more information on Sapience Therapeutics, please visitwww.sapiencetherapeutics.comand engage with us onLinkedIn.

Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements. Any statements herein other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties (including with respect to Sapience's preclinical and clinical development programs). These forward-looking statements are based on management's current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. Forward-looking statements speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise, except as required by law.

ContactsSapience Therapeutics, Inc.Barry Kappel, Ph.D., M.B.A.President and Chief Executive Officer[emailprotected]

Media and Investor Contact:Amy ConradJuniper Point(858) 366-3243[emailprotected]

SOURCE Sapience Therapeutics

Read the original here:
Sapience Therapeutics Announces Publication Showcasing the Mechanism of Action and Anti-tumor Activity of ST101, a Novel and Selective Peptide...

A Yellowknife resident is calling on the Northwest Territories government to offer an HIV preventative drug at no cost to residents without health insurance.

William Gagnon saidHIV pre-exposure prophylaxis(PrEP), a daily pill taken by those at high risk of contracting HIV,isn't covered by theN.W.T.government for those without health insurance.

Meaning residents in need wouldhave to pay out of pocket.

"If you don't [have insurance]then it could be a big financial barrier," Gagnon told CBC News.

"So I just think it should be universal coverage."

The drug is found beeffective at preventing HIV when taken as prescribedand iscovered for residents inseveral other jurisdictions includingthe Yukon, Manitoba, B.C., Saskatchewan and Alberta.

Jeremy Bird, a spokesperson for the Health Department, said in an emailthe current policy doesn't offer the drug because the N.W.T.'s Specified Disease Conditions Extended Health Benefits program coverage requires a diagnosis of a specified condition. He said it costs around $1,000 a month for those not covered to pay for it. Gagnon said in the petition for those without health insurancePrEPcosts around $250 a month.

However, most employer insurance plans cover PrEP,as well as non-insuredhealth benefits programs for First Nations, Inuit and Mtis.

Gagnon started a petition that encourages residents to fill out a feedback form the territorial government is collecting on proposed changes to the extended health benefits policy.

The territory is proposing extending coveragefor those who don't have health insurance and make under a certain amount annually.

The changeswould makePrEP free for those who fit into that category.

The feedback form said the N.W.T. hasn't updated its health benefits policy in 34 years and is doing so to ensure it meets theobjectives of fairness and equity.

Chelsea Thacker, the executive director of the Northern Mosaic Network,said it's good the N.W.T. is taking feedback, but thatPrEPshould have been offered to residents long before this.

"We shouldn't even be debating preventative health care measures and the access to it," they said.

"So many people need access to this medication in order to safely engage in physical contact with their partner."

Thacker addedPrEP should be available to all, no matter their income.

"Basing it off people's income isn't necessarily something that we have the right to do," they said.

"A lot of people have different expenses that we don't know about. And so really with so many things still needing to be paid inour health-care system, I think that this medication should just be free for everyone."

The territory has only had five cases of HIV diagnosed in the past five years, according to data provided by the Health Department.

However, sexually transmitted infections (STIs) rates as a whole are among the highest in the country and the territory is in the midst of an unprecedented syphilis outbreak.

Sean Hosein is a science and medicine editor with Catie.ca, a Canadian information website on HIV and other STIs.

He said a syphilis infection makes it easier for HIV to be transmitted due to genital inflammation or lesions.

"So when you've got inflammationinside your genitals or on them, or tiny holes or lesions, then not only can you spread syphilis to other people, but you can get other germs, including HIV," Hosein said.

He said in the long run,preventative drugs like PrEP are far more cost effective thantreatment.

"It's always cheaper and easier and simpler to prevent something rather than wait until it gets more complicated down the road," he said.

"So the costs of PrEPare really low compared to the lifetime cost for treating chronic HIV infection."

As of Friday afternoon, nearly 2,000people had signed Gagnon's petition which was started on Tuesday.

Residents interested in sharing feedback on the proposed changes to the N.W.T. extended health benefits have until Oct. 14 to do so.

Go here to see the original:
As N.W.T. mulls health coverage changes, petition calls for preventative HIV drug to be free - CBC.ca

People pose with syringe with needle in front of displayed AstraZeneca logo in this illustration taken, December 11, 2021. REUTERS/Dado Ruvic/Illustration/Files

Register now for FREE unlimited access to Reuters.comRegister

LONDON, Sept 16 (Reuters) - Europe's medicines regulator has backed using AstraZeneca's (AZN.L) preventative COVID-19 therapy as a treatment for the disease and also endorsed another medicine as preventative option for another common virus.

The regulator's recommendations are usually followed by the European Commission when it takes a final decision on drug approvals.

AstraZeneca said on Friday the European Medicines Agency (EMA) had backed Evusheld as a treatment for adults and adolescents with COVID who do not need supplemental oxygen and who are at increased risk of their disease worsening.

Register now for FREE unlimited access to Reuters.comRegister

Last month, Japan became the first country to approve the long-acting antibody as a treatment for COVID - making Evusheld the first such therapy authorised for both prevention and treatment of the viral disease.

Evusheld had previously had largely secured global approvals, including in Europe, as a preventative therapy for people with compromised immune systems who see little or no benefit from COVID vaccines.

AstraZeneca is leaning on Evusheld to help offset tepid sales of its COVID vaccine that has rapidly lost ground to mRNA shots in the fight against the rapidly evolving virus.

Evusheld, first launched in December, generated $914 million in the first half of 2022 for the Anglo-Swedish drugmaker.

Separately on Friday, the EMA also endorsed AstraZeneca and partner Sanofi's experimental long-acting therapy Beyfortus for the prevention of lower respiratory tract infections caused by respiratory syncytial virus (RSV).

RSV causes thousands of hospitalisations and deaths globally each year in toddlers and the elderly, but the complex molecular structure of the virus and safety concerns have stymied efforts to develop a vaccine since the virus was first discovered in 1956.

But there is one therapy, Synagis, also developed by AstraZeneca but sold by Swedish Orphan Biovitrum (SOBIV.ST) in the United States.

It is designed to prevent lower respiratory tract infections caused by RSV in high-risk infants and requires up to five injections to cover a typical RSV season.

Meanwhile, if Beyfortus were approved, it would be the first single-dose preventative RSV therapy for the broad infant population - including those born healthy or are deemed high-risk - during their first RSV season.

Register now for FREE unlimited access to Reuters.comRegister

Reporting by Pushkala Aripaka in Bengaluru and Natalie Grover in London; editing by Mark Potter and Jason Neely

Our Standards: The Thomson Reuters Trust Principles.

Read the original:
EU regulator backs wider use of AstraZeneca COVID therapy - Reuters

For those who dont know, integrative medicine is the blending of conventional medicine with complementary or alternative medicine.

Essentially, an integrative treatment is one that utilizes traditional drugs and surgery in combination with other holistic therapies such as Ayurveda, homeopathy, acupuncture, yoga, meditation and massages.

This medical practice doesnt just remedy a patients disease or pain. It also dives deeply into the patients physical, emotional, spiritual and pathophysiological wellness.

Integrative medicine is preventative and curative, just like conventional medicine, but it also brings forth a dimension of healing that conventional medicine and alternative medicine simply cant reach on their own.

It is understandable why people tend to be skeptical about alternative medicine. After all, the scientific evidence proving the legitimacy of alternative treatments is just beginning to roll out.

Additionally, alternative medical treatments are known to take much longer to work than conventional treatments. This is because every health issue is dealt with at its root by promoting lifestyle changes, emotional/spiritual wellness therapies and natural (non-lab-made) medication. Therefore, alternative medicine is not the best option in emergency situations.

On the other side, alternative medicine patients do receive personal attention and tailored treatment plans to heal not only their ailments but also their body and mind.

Patients often feel long-term betterment due to the fact that they are given the lifestyle tools to promote further healing. Alternative medicine patients also tend to suffer less from the side effects of their medication.

Last but not least, alternative medicine is much more affordable than conventional medicine.

On the other hand, conventional medicine is widely accepted throughout the world, especially in western societies. There is a lot of scientific evidence proving the effectiveness of conventional medicine.

It is especially great in emergency situations and can be helpful if a patient wants to treat an illness and its symptoms quickly.

Unfortunately, conventional medicine does fall short since treatment is often localized to where the disease or pain is rather than treating a patient on the whole.

In these ways, conventional medicine might not be the best in cases of chronic pain and illness.

Alternative medicine and conventional medicine both have drawbacks and benefits, but together they make an incredible treatment plan.

Where one falls short the other pulls through and vice versa. The best example is a cancer patient.

Telling a cancer patient to only take natural medication and to practice yoga to rid themselves of the cancer is impractical.

Telling a cancer patient to go through chemotherapy without accounting for other facets of their wellness is also impractical.

A patient should go through chemo while also focusing on alternative medicine treatments such as inflammatory food avoidance.

As time passes, studies increasingly show that there is a strong connection between mind and body when it comes to illness.

For example, studies have demonstrated that depression is a risk factor for heart disease.

The mind and body affect one another, so a successful, sustainable treatment would address mind-body related health issues along with physical issues.

For example, studies show that Cognitive Behavioral Therapy in combination with highly active antiretroviral therapy is a great combination to treat HIV-positive men.

In this treatment, both mind and body are looked after to foster the long-term healing of HIV-positive men.

While alternative medicine works best for some people, and conventional medicine works better for others, it is the gap that integrative medicine bridges that truly promotes sustainable and successful health and wellness.

Original post:
Choose integrative medicine for health and wellness - Technique